Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
Yonghan He, Sajid Khan, Zhiguang Huo, et al.
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 87

Showing 1-25 of 87 citing articles:

PROTAC targeted protein degraders: the past is prologue
Miklós Békés, David R. Langley, Craig M. Crews
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 3, pp. 181-200
Open Access | Times Cited: 1681
N6-methyladenosine methyltransferases: functions, regulation, and clinical potential
Wei Huang, Tian-Qi Chen, Ke Fang, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 172
Targeting Akt in cancer for precision therapy
Hui Hua, Hongying Zhang, Jingzhu Chen, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 154
Target and tissue selectivity of PROTAC degraders
Robert G. Guenette, Seung Wook Yang, Jaeki Min, et al.
Chemical Society Reviews (2022) Vol. 51, Iss. 14, pp. 5740-5756
Closed Access | Times Cited: 125
Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity,
Dongwen Lv, Pratik Pal, Xingui Liu, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 99
Mantle cell lymphoma in 2022—A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments
Preetesh Jain, Michael Wang
American Journal of Hematology (2022) Vol. 97, Iss. 5, pp. 638-656
Closed Access | Times Cited: 87
E3 ligase ligand chemistries: from building blocks to protein degraders
Izidor Sosič, Aleša Bricelj, Christian Steinebach
Chemical Society Reviews (2022) Vol. 51, Iss. 9, pp. 3487-3534
Closed Access | Times Cited: 87
E3 ligases and deubiquitinating enzymes regulating the MAPK signaling pathway in cancers
Hong‐Beom Park, Kwang‐Hyun Baek
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2022) Vol. 1877, Iss. 3, pp. 188736-188736
Closed Access | Times Cited: 84
Tumor Abnormality-Oriented Nanomedicine Design
Quan Zhou, Jiajia Xiang, Nasha Qiu, et al.
Chemical Reviews (2023) Vol. 123, Iss. 18, pp. 10920-10989
Closed Access | Times Cited: 61
Expanding PROTACtable genome universe of E3 ligases
Yuan Liu, Jingwen Yang, Tianlu Wang, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 53
Chemically engineering cells for precision medicine
Yixin Wang, Zhaoting Li, Fanyi Mo, et al.
Chemical Society Reviews (2023) Vol. 52, Iss. 3, pp. 1068-1102
Closed Access | Times Cited: 40
MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents
Arnold Bolomsky, Meike Vogler, Murat Cem Köse, et al.
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 124
Current status and future perspectives in targeted therapy of NPM1-mutated AML
Roberta Ranieri, Giulia Pianigiani, Sofia Sciabolacci, et al.
Leukemia (2022) Vol. 36, Iss. 10, pp. 2351-2367
Open Access | Times Cited: 61
Protein degradation technology: a strategic paradigm shift in drug discovery
Haobin Li, Jinyun Dong, Mao-Hua Cai, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 60
BCR-ABL1 Tyrosine Kinase Complex Signaling Transduction: Challenges to Overcome Resistance in Chronic Myeloid Leukemia
Gustavo P. Amarante-Mendes, Aamir Rana, Tarcila Santos Datoguia, et al.
Pharmaceutics (2022) Vol. 14, Iss. 1, pp. 215-215
Open Access | Times Cited: 50
Progress and Challenges in Targeted Protein Degradation for Neurodegenerative Disease Therapy
Yingxu Fang, Jiaxing Wang, Min Zhao, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 17, pp. 11454-11477
Closed Access | Times Cited: 44
Recent Advances in PROTAC-Based Antiviral Strategies
Haleema Ahmad, Bushra Zia, Hashir Husain, et al.
Vaccines (2023) Vol. 11, Iss. 2, pp. 270-270
Open Access | Times Cited: 25
The ubiquitin codes in cellular stress responses
Xiangpeng Sheng, Zhixiong Xia, Hanting Yang, et al.
Protein & Cell (2023) Vol. 15, Iss. 3, pp. 157-190
Open Access | Times Cited: 24
PROTACs: A novel strategy for cancer drug discovery and development
Xin Han, Yi Sun
MedComm (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 23
Restraining the power of Proteolysis Targeting Chimeras in the cage: A necessary and important refinement for therapeutic safety
Renshuai Zhang, Songbo Xie, Jie Ran, et al.
Journal of Cellular Physiology (2024) Vol. 239, Iss. 5
Closed Access | Times Cited: 9
Discovery of Effective Dual PROTAC Degraders for Neurodegenerative Disease-Associated Aggregates
Wentao Zhu, Wenqian Zhang, Jian Chen, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 5, pp. 3448-3466
Closed Access | Times Cited: 8
PROTAC-Mediated GSPT1 Degradation Impairs the Expression of Fusion Genes in Acute Myeloid Leukemia
Alicia Perzolli, Christian Steinebach, Jan Krönke, et al.
Cancers (2025) Vol. 17, Iss. 2, pp. 211-211
Open Access
Identification of novel 7-hydroxycoumarin derivatives as ELOC binders with potential to modulate CRL2 complex formation
Y. Kim, Seung Jae Baek, Eun-Kyung Yoon, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Senolytic targets and new strategies for clearing senescent cells
Ming‐Xia Ge, Hu Li, Hong-Shun Ao, et al.
Mechanisms of Ageing and Development (2021) Vol. 195, pp. 111468-111468
Closed Access | Times Cited: 45
The Omnipresence of DYRK1A in Human Diseases
Estelle Deboever, Alessandra Fistrovich, Christopher Hulme, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 16, pp. 9355-9355
Open Access | Times Cited: 31
Page 1 - Next Page

Scroll to top